Switch theme
Sign up to access all valuation multiples
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
1995
7K+
LTM Revenue $2.9B
LTM EBITDA $371M
$12.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Exact Sciences has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $371M.
In the most recent fiscal year, Exact Sciences achieved revenue of $2.8B and an EBITDA of -$789M.
Exact Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Exact Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | $2.1B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $371M | XXX | -$789M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | -29% | XXX | XXX | XXX |
| EBIT | -$620M | XXX | -$179M | XXX | XXX | XXX |
| EBIT Margin | -21% | XXX | -6% | XXX | XXX | XXX |
| Net Profit | -$657M | XXX | -$1.0B | XXX | XXX | XXX |
| Net Margin | -23% | XXX | -37% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Exact Sciences's stock price is $56.
Exact Sciences has current market cap of $10.6B, and EV of $12.4B.
See Exact Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.4B | $10.6B | XXX | XXX | XXX | XXX | $-3.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Exact Sciences has market cap of $10.6B and EV of $12.4B.
Exact Sciences's trades at 4.5x EV/Revenue multiple, and -15.6x EV/EBITDA.
Equity research analysts estimate Exact Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Exact Sciences has a P/E ratio of -16.2x.
See valuation multiples for Exact Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.6B | XXX | $10.6B | XXX | XXX | XXX |
| EV (current) | $12.4B | XXX | $12.4B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 33.3x | XXX | -15.6x | XXX | XXX | XXX |
| EV/EBIT | -19.9x | XXX | -68.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -16.2x | XXX | -10.3x | XXX | XXX | XXX |
| EV/FCF | 88.2x | XXX | 165.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialExact Sciences's last 12 month revenue growth is 13%
Exact Sciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Exact Sciences's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Exact Sciences's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Exact Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | -29% | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | 287% | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | -16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Exact Sciences acquired XXX companies to date.
Last acquisition by Exact Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Exact Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Exact Sciences founded? | Exact Sciences was founded in 1995. |
| Where is Exact Sciences headquartered? | Exact Sciences is headquartered in United States of America. |
| How many employees does Exact Sciences have? | As of today, Exact Sciences has 7K+ employees. |
| Who is the CEO of Exact Sciences? | Exact Sciences's CEO is Mr. Kevin T. Conroy. |
| Is Exact Sciences publicy listed? | Yes, Exact Sciences is a public company listed on NAS. |
| What is the stock symbol of Exact Sciences? | Exact Sciences trades under EXAS ticker. |
| When did Exact Sciences go public? | Exact Sciences went public in 2001. |
| Who are competitors of Exact Sciences? | Similar companies to Exact Sciences include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Exact Sciences? | Exact Sciences's current market cap is $10.6B |
| What is the current revenue of Exact Sciences? | Exact Sciences's last 12 months revenue is $2.9B. |
| What is the current revenue growth of Exact Sciences? | Exact Sciences revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Exact Sciences? | Current revenue multiple of Exact Sciences is 4.3x. |
| Is Exact Sciences profitable? | Yes, Exact Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Exact Sciences? | Exact Sciences's last 12 months EBITDA is $371M. |
| What is Exact Sciences's EBITDA margin? | Exact Sciences's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Exact Sciences? | Current EBITDA multiple of Exact Sciences is 33.3x. |
| What is the current FCF of Exact Sciences? | Exact Sciences's last 12 months FCF is $140M. |
| What is Exact Sciences's FCF margin? | Exact Sciences's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Exact Sciences? | Current FCF multiple of Exact Sciences is 88.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
